Logo image
The impact of immuno-aging on SARS-CoV-2 vaccine development
Journal article   Open access   Peer reviewed

The impact of immuno-aging on SARS-CoV-2 vaccine development

Jennifer Connors, Matthew R. Bell, Jennifer Marcy, Michele Kutzler and Elias K. Haddad
GeroScience, v 43(1), pp 1-21
11 Feb 2021
PMID: 33569701
url
https://doi.org/10.1007/s11357-021-00323-3View
Published, Version of Record (VoR)Maybe Open Access (Publisher Bronze) Open

Abstract

(4–6): SARS-CoV-2 Adjuvants Aging Original Vaccine delivery platforms Vaccines
The SARS-CoV-2 pandemic has almost 56 million confirmed cases resulting in over 1.3 million deaths as of November 2020. This infection has proved more deadly to older adults (those >65 years of age) and those with immunocompromising conditions. The worldwide population aged 65 years and older is increasing, and the total number of aged individuals will outnumber those younger than 65 years by the year 2050. Aging is associated with a decline in immune function and chronic activation of inflammation that contributes to enhanced viral susceptibility and reduced responses to vaccination. Here we briefly review the pathogenicity of the virus, epidemiology and clinical response, and the underlying mechanisms of human aging in improving vaccination. We review current methods to improve vaccination in the older adults using novel vaccine platforms and adjuvant systems. We conclude by summarizing the existing clinical trials for a SARS-CoV-2 vaccine and discussing how to address the unique challenges for vaccine development presented with an aging immune system.

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Geriatrics & Gerontology
Logo image